

RAD51C and RAD51D: **CanVIG-UK Gene-Specific Guidance**

Date: 07/10/2025 Version: 1.3

A. Garrett^{1,2}, S. Allen¹, L. Loong¹, M. Durkie³, G.J. Burchell^{4,5}, R. Robinson⁶, A. Callaway⁷, J. Field⁸, B. Frugtiet², S. Palmer-Smith⁹, J. Grant¹⁰, J. Pagan¹¹, T. McDevitt¹², L. Hughes¹³, K. Snape², T. McVeigh¹⁴, H. Hanson^{15,16}, C. Turnbull^{1,14}

1. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
2. St George's University Hospitals NHS Foundation Trust, Tooting, London, UK
3. North East and Yorkshire Genomic Laboratory Hub, Sheffield Children's NHS Foundation Trust, Sheffield, UK
4. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
5. Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
6. The Leeds Genetics Laboratory, NEY Genomic Laboratory Hub, Leeds Teaching Hospitals NHS Trust, Leeds, UK
7. Central and South Genomics Laboratory Hub, Wessex Genomics Laboratory Service, University Hospital Southampton NHS Foundation Trust, Salisbury, UK.
8. Genomics and Molecular Medicine Service, Nottingham University Hospitals NHS Trust, Nottingham, UK
9. Wales Genomic Health Centre, Cardiff and Vale University Health Board, Cardiff, UK
10. Laboratory Genetics, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
11. South East Scotland Clinical Genetics, Western General Hospital, Edinburgh, UK.
12. Department of Clinical Genetics, CHI at Crumlin, Dublin, Ireland
13. West Midlands Genomics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
14. The Royal Marsden NHS Foundation Trust, Fulham Road, London
15. Peninsula Regional Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
16. Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom

CanVIG-UK review of RAD51C and RAD51D: Consensus to use relevant recommendations from the ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for **ATM Version 1.4.0** (available at: <https://clinicalgenome.org/affiliation/50039/>, PDF attached below). Additional points of specification are given below where applicable.

Additional Note: This guidance is intended for use in classification of truncating variants only as per the current UK test directory.

Summary: Evidence towards Pathogenicity

Summary of Evidence towards Pathogenicity																																										
Evidence element	Evidence strengths allowed				Use as per VCEP	Additional clarifications/thresholds/data-sources																																				
PVS1	_VSTR	_STR	_MOD	_SUP	X	From CanVIG-UK: For <i>RAD51C</i>, as per draft <i>RAD51C</i> VCEP guidance (not yet published): - PVS1 is not applicable for the initiation codon or for any nonsense variants 5' of p.M10 - PVS1_vstr may be applied for exon deletions affecting the Walker-A region (p.125-132) - PVS1_vstr may be applied for exon deletions removing >10% of the protein (<113nt, <38 aa) - For the following 1,2 splice sites, apply PVS1 at the following evidence strengths: <table><thead><tr><th>Position</th><th>Strength</th><th>Position</th><th>Strength</th></tr></thead><tbody><tr><td>c.145+1</td><td>VSTR</td><td>c.145+2</td><td>VSTR</td></tr><tr><td>c.146-1</td><td>VSTR</td><td>c.146-2</td><td>VSTR</td></tr><tr><td>c.404+1</td><td>VSTR</td><td>c.404+2</td><td>VSTR</td></tr><tr><td>c.405-1</td><td>VSTR</td><td>c.405-2</td><td>VSTR</td></tr><tr><td>c.571+1</td><td>VSTR</td><td>c.571+2</td><td>VSTR</td></tr><tr><td>c.572-1</td><td>VSTR</td><td>c.572-2</td><td>VSTR</td></tr><tr><td>c.705+1</td><td>VSTR</td><td>c.705+2</td><td>VSTR</td></tr><tr><td>c.706-1</td><td>VSTR</td><td>c.706-2A>C, A>T</td><td>VSTR</td></tr></tbody></table>	Position	Strength	Position	Strength	c.145+1	VSTR	c.145+2	VSTR	c.146-1	VSTR	c.146-2	VSTR	c.404+1	VSTR	c.404+2	VSTR	c.405-1	VSTR	c.405-2	VSTR	c.571+1	VSTR	c.571+2	VSTR	c.572-1	VSTR	c.572-2	VSTR	c.705+1	VSTR	c.705+2	VSTR	c.706-1	VSTR	c.706-2A>C, A>T	VSTR
Position	Strength	Position	Strength																																							
c.145+1	VSTR	c.145+2	VSTR																																							
c.146-1	VSTR	c.146-2	VSTR																																							
c.404+1	VSTR	c.404+2	VSTR																																							
c.405-1	VSTR	c.405-2	VSTR																																							
c.571+1	VSTR	c.571+2	VSTR																																							
c.572-1	VSTR	c.572-2	VSTR																																							
c.705+1	VSTR	c.705+2	VSTR																																							
c.706-1	VSTR	c.706-2A>C, A>T	VSTR																																							

						<table><tr><td></td><td></td><td>c.706-2A>G</td><td>STR</td></tr><tr><td>c.837+1</td><td>STR</td><td>c.837+2</td><td>STR</td></tr><tr><td>c.838-1</td><td>VSTR</td><td>c.838-2</td><td>VSTR</td></tr><tr><td>c.904+1</td><td>VSTR</td><td>c.904+2</td><td>VSTR</td></tr><tr><td>c.905-1</td><td>STR</td><td>c.905-2</td><td>STR</td></tr><tr><td>c.965+1</td><td>STR</td><td>c.965+2</td><td>STR</td></tr><tr><td>c.966-1</td><td>SUP</td><td>c.966-2</td><td>SUP</td></tr><tr><td>c.1026+1</td><td>STR</td><td>c.1026+2</td><td>STR</td></tr><tr><td>c.1027-1</td><td>N/A</td><td>c.1027-2</td><td>N/A</td></tr></table>			c.706-2A>G	STR	c.837+1	STR	c.837+2	STR	c.838-1	VSTR	c.838-2	VSTR	c.904+1	VSTR	c.904+2	VSTR	c.905-1	STR	c.905-2	STR	c.965+1	STR	c.965+2	STR	c.966-1	SUP	c.966-2	SUP	c.1026+1	STR	c.1026+2	STR	c.1027-1	N/A	c.1027-2	N/A
		c.706-2A>G	STR																																							
c.837+1	STR	c.837+2	STR																																							
c.838-1	VSTR	c.838-2	VSTR																																							
c.904+1	VSTR	c.904+2	VSTR																																							
c.905-1	STR	c.905-2	STR																																							
c.965+1	STR	c.965+2	STR																																							
c.966-1	SUP	c.966-2	SUP																																							
c.1026+1	STR	c.1026+2	STR																																							
c.1027-1	N/A	c.1027-2	N/A																																							
						For <i>RAD51D</i>, follow Tayoun <i>et al.</i> 2018¹ guidance until boundaries specified by the VCEP. *For both genes, follow <i>ATM</i> VCEP guidance for PVS1(RNA), see below: - PVS1_Variable(RNA) shall be used for observed splice defects, whether from canonical +/-1,2 positions or other spliceogenic regions (including mid-exonic missense/synonymous variants that cause splice defects) with baseline weight as per the below decision tree. Weight can be further modified based on the quality of the RNA study including consideration of concepts such as: - Starting material (where patient material is preferable to in vitro minigene) - Use of NMD inhibitors where translation does occur such as cell lines - Primer design (to make sure it's comprehensive to capture possible multicassette events) - Method of quantification - where e.g. capillary electrophoresis is preferable to estimation by gel band density - where SNP analysis is most preferred (where analysis of exonic SNPs and their relative presence in aberrant and WT transcripts is informative) - Quantification (where complete effects should have increased weight over incomplete effects) In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA).																																				
PS1		_STR	_MOD	_SUP	✓																																					
PS2						✓																																				
PS3		_STR	_MOD	_SUP	✓																																					
PS4		_STR			✓																																					
PM1						✓																																				
PM2				_SUP	X	From CanVIG-UK: Use <u>female-only</u> population controls From VCEP: Per correspondence: 30/07/2025: - If grpmax FAF ≤0.001% (regardless of n) - apply PM2_sup - If grpmax FAF not calculated (typically due to low n), look at highest ancestry AF: - If ≤0.001% (regardless of n) apply PM2_sup - If >0.001% but only n=1 in one population, apply PM2_sup																																				

						- Otherwise, no criteria - If grpmx FAF >0.001%, do not apply PM2_sup even if there is only one ancestry group with variant and ancestry AF is ≤0.001%
PM3	_VSTR	_STR	_MOD	_SUP	X	From CanVIG-UK: Please refer to the CanVIG-UK <i>BRCA2</i> guidance for application for biallelic Fanconi anaemia.
PM4			_MOD		✓	
PM5				_SUP	X	From CanVIG-UK: PM5 may be applied at supporting level for truncating variants in nonsense mediated decay (NMD) is predicted: <i>RAD51C</i>: NMD predicted if the variant is 5' of p.Leu326 <i>RAD51D</i>: gene-specific NMD boundary not yet established; assume NMD unless in the final exon or the last 50 base pairs of the penultimate exon.
PP1		_STR	_MOD	_SUP	✓	From VCEP: As per VCEP, please note PP1 may only be used for autosomal recessive conditions, not autosomal dominant.
PP2					✓	
PP3				_SUP	✓	
PP4					✓	
PP5					✓	

Summary: Evidence towards Benignity

BA1/BS1	_SA	_STR			X	From CanVIG-UK: <i>RAD51C</i> draft VCEP guidance states MTAF of: BA1: 0.000583 (0.0583%) BS1: 0.0000583 (0.00583%) The MTAF (maximum tolerated allele frequency) has been calculated using cardiodb using the calculate AF function: prevalence 1 in 78; genetic heterogeneity 0.01; allelic heterogeneity 1 (BA1) 0.1 (BS1); penetrance 0.11. Cancer-free female controls should be used when determining the maximum allele count / filtering allele frequency; therefore it is permissible to use the cancer-free GrpMAX FAF on gnomAD against the MTAF cutoffs for BA1/BS1. See consensus guidelines for further details on GrpMAX FAF, and the use of cardiodb for calculating the maximum allele count / filtering allele frequency.
BS2					✓	
BS3			_MOD	_SUP	✓	
BS4					✓	
BP1					✓	
BP2		_STR	_MOD	_SUP	✓	
BP3					✓	
BP4				_SUP	✓	
BP5					✓	
BP7		_STR	_MOD	_SUP	✓	

Version History/Amendments

Revised version	Date	Section	Update	Amended by	Approved by
1.0	28/09/2023	--	Initial Version	--	CStAG
v1.1	25/01/2024	Statement	Update to opening statement to reference most current VCEP version (v1.3.0)	Allen	CStAG
v1.1	10/05/2024	PM2	Updated to match statement for CanVIG ATM guidelines (to use gnomAD v2.1.1 per VCEP correspondence), and to use female-only sex-matched controls	Allen	CStAG
v1.2	21/06/2024	PS4/BA1/BS1	For consistency with PM2, updated to specify female-only sex-matched controls, and updated terminology per gnomAD (PopMax FAF updated to GrpMax FAF)	Allen	CStAG
1.3	07/10/2025	Statement	Update to reference current VCEP version (v1.4.0)	Allen	CStAG
1.3	07/10/2025	PVS1	Updated default guidance for RAD51D to Tayoun et al 2018	Allen	CStAG
1.3	07/10/2025	PM2	Added clarification for application of PM2 _{sup} when n=1 in gnomAD v4.1	Allen	CStAG

References

1 Abou Tayoun AN, Pesaran T, DiStefano MT, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat.* 2018;39(11):1517-1524. doi:10.1002/humu.23626

Criteria Specification

ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ATM Version 1.4.0

Affiliation: Hereditary Breast, Ovarian and Pancreatic Cancer VCEP
Type: Richards et.al., 2015 - Combining rules
Description : ACMG-modified rules specifications for ATM (autosomal dominant and autosomal recessive disorders)
Version : 1.4.0
Released : 7/14/2025
Release Notes :
Release notes v1.4

Removed n for PM2_Supporting and clarified use of gnomAD v4
Clarified when to assume in trans for PM3
Provided PP1 guidance for AR condition
Added SpliceAI thresholds for PP3 and BP4
Clarified use of PP3/BP4 in the presence of RNA data
Updated BP7 donor site cutoff from c.-40 to c.-21
Updated MONDO from hereditary breast carcinoma to ATM-related cancer predisposition
Minor formatting adjustments

Rules for ATM

General Comments: Release notes v1.4 Removed n for PM2_Supporting and clarified use of gnomAD v4 Clarified when to assume in trans for PM3 Provided PP1 guidance for AR condition Added SpliceAI thresholds for PP3 and BP4 Clarified use of PP3/BP4 in the presence of RNA data Updated BP7 donor site cutoff from c.-40 to c.-21 Updated MONDO from hereditary breast carcinoma to ATM-related cancer predisposition Minor formatting adjustments

Gene: ATM (HGNC:795) ↗ Transcripts: NM_000051.3	HGNC Name: ATM serine/threonine kinase Disease: ATM-related cancer predisposition (MONDO:0700270) ↗ Mode of Inheritance: Autosomal dominant inheritance ataxia telangiectasia (MONDO:0008840) ↗ Mode of Inheritance: Autosomal recessive inheritance ataxia - telangiectasia variant (MONDO:0018266) ↗ Mode of Inheritance: Autosomal recessive inheritance
---	--

Criteria & Strength Specifications

PVS1

Original ACMG

Summary

Null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.

Caveats:

- Beware of genes where LOF is not a known disease mechanism (e.g. GFAP, MYH7).
- Use caution interpreting LOF variants at the extreme 3' end of a gene.
- Use caution with splice variants that are predicted to lead to exon skipping but leave the remainder of the protein intact.
- Use caution in the presence of multiple transcripts.

VCEP

Use ATM PVS1 Decision Tree.

Specifications:

- PVS1: Predicted splice defect
- PVS1_Strength(RNA): Observed splice defect
- The default RefSeq transcript for nucleotide (c.) annotation is **NM_000051.3/ENST00000278616.8**. All exons from this transcript can be considered constitutive exons without major alternate splice isoforms that could potentially rescue presumed LoF events (ENIGMA unpublished data).
- Of note, ATM is occasionally annotated with multiple non-coding first exons so exon numbering must be carefully reviewed for variant interpretation using literature sources of data.
- **The FAT/PI3K/FATC (collectively the FATKIN) domains** are considered *critical* for ATM protein function (PMID 28508083, 31740029, 31320732). PVS1 alterations that are predicted to escape NMD, but that adversely affect these domains can be granted PVS1 (as opposed to PVS1_Strong as the recommended base-line (PMID 30192042)).
- **The HEAT repeat domain** is considered *important* for protein function based on the appearance of many A-T affected individuals harboring a variant resulting in an in-frame, single exon loss in this domain (PMID 10980530, 19535770, 30819809, 15054841, 22927201, 19691550, 10330348, 17124347, 8845835, 16266405, 9463314, 24090759, 22213089). PVS1-eligible alterations that are predicted to escape NMD, but that adversely affect the HEAT repeat domain can be granted PVS1_Strong. They are limited to strong due to a lack of known missense pathogenic alterations in this domain.
- The most 3'/C-Terminal residue considered to be pathogenic is p.R3047 (PMIDs: 8755918, 19691550, 18560558, 10980530,

26628246)

- NOTE: Many diagrams for ATM show the FAT, PI3-K and FATC domains as separated by spacers, however these are not empirically derived and there is evidence of missense pathogenic alterations in the 'spacer' regions. This VCEP considers them a contiguous domain (PMID 28508083).
- PVS1 can be applied as per the PVS1 decision tree.
 - PVS1_Variable(RNA) shall be used for observed splice defects, whether from canonical +/-1,2 positions or other spliceogenic regions (including mid-exonic missense/synonymous variants that cause splice defects) with baseline weight as per the below decision tree. Weight can be further modified based on the quality of the RNA study including consideration of concepts such as:
 - Starting material (where patient material is preferable to in vitro minigene)
 - Use of NMD inhibitors where translation does occur such as cell lines⁵⁶
 - Primer design (to make sure it's comprehensive to capture possible multicassette events)
 - Method of quantification
 - where e.g. capillary electrophoresis is preferable to estimation by gel band density
 - where SNP analysis is most preferred (where analysis of exonic SNPs and their relative presence in aberrant and WT transcripts is informative)
 - Quantification (where complete effects should have increased weight over incomplete effects)
 - Specific guidance on the use of RNA evidence in variant assessment is not a gene-specific consideration for PALB2 at this time, therefore discretion is left to assessors until further guidance is provided for this general concept from the Sequence Variant Interpretation group.
- In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA).

Very Strong

Use ATM PVS1 Decision Tree

Modification Gene-specific,Strength

Type:

Strong

Use ATM PVS1 Decision Tree.

Modification Gene-specific,Strength
Type:

Moderate

Use ATM PVS1 Decision Tree.

Modification Gene-specific,Strength
Type:

Supporting

Use ATM PVS1 Decision Tree

Modification Gene-specific,Strength
Type:

PS1

**Original ACMG
Summary**

Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Example: Val->Leu caused by either G>C or G>T in the same codon.
Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.

VCEP Specifications:

- Use as ascribed for missense changes as long as a splice defect is ruled out for both variants;
- Use ATM PS1 Splicing table for splicing variants with similar predictions or observations of splice defect. (PMID: 36865205)

Strong

- Use for missense changes as long as splicing is ruled-out for both alterations.
- Use ATM PS1 Splicing table for splicing variants with similar predictions or observations of splice defect.

Modification General recommendation
Type:

Moderate

Use ATM PS1 Splicing table for splicing variants with similar predictions or observations of splice defect.

Modification General recommendation,Strength
Type:

Supporting

Use ATM PS1 Splicing table for splicing variants with similar predictions or observations of splice defect.

Modification General recommendation, Strength
Type:

PS2

Original ACMG Summary

De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.

Note: Confirmation of paternity only is insufficient. Egg donation, surrogate motherhood, errors in embryo transfer, etc. can contribute to non-maternity.

Not Applicable

Comments: Do not use for AD or AR disease: Informative de novo occurrences have not yet been observed and de novo AR conditions are unlikely to be informed by phase

PS3

Original ACMG Summary

Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.

Note: Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established.

VCEP For protein, see detailed notes on ATM-specific assays; For RNA use code
Specifications PVS1_Strength(RNA) and modulate strength based on assay quality and quantity (curator discretion).

Strong

Do not use as strong.

Modification Gene-specific
Type:

Moderate

Use when a variant fails to rescue both an ATM specific feature (e.g. phosphorylation of ATM-specific targets) AND radiosensitivity.

Modification Gene-specific, Strength
Type:

Supporting

Use when a variant fails to rescue an ATM specific feature, only (e.g. phosphorylation of ATM-specific targets). Do not use for radiosensitivity-only as that is not a feature specific to ATM deficiency

Modification Gene-specific, Strength
Type:

PS4

Original ACMG Summary

The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls.

Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0. See manuscript for detailed guidance.

Note 2: In instances of very rare variants where case-control studies may not reach statistical significance, the prior observation of the variant in multiple unrelated patients with the same phenotype, and its absence in controls, may be used as moderate level of evidence.

VCEP PS4_Moderate: Do not use. Proband counting for genes causing a common
Specifications disorder need to be calibrated in a population-specific way before use.

Strong

Case-control studies; $p\text{-value} \leq .05$ AND (Odds ratio, hazard ratio, or relative risk ≥ 2 OR lower 95% CI ≥ 1.5).

Modification General recommendation
Type:

PM1

Original ACMG Summary

Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.

Not Applicable

Comments: Do not use: Benign and pathogenic variants are known to occur within the same domains and germline mutational hotspots are not well defined at this time

PM2

Original ACMG

Summary

Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.

Caveat: Population data for indels may be poorly called by next generation sequencing.

VCEP

Specifications:

- Is not considered a conflicting piece of evidence for variants that otherwise are likely benign/benign
- Use as **PM2_Supporting** (not moderate)

Supporting

Frequency $\leq .001\%$ in gnomAD v4 dataset

If $n=1$ in a single sub population, that is sufficiently rare and PM2_supporting would apply.

Modification Gene-specific, Strength

Type:

PM3

Original ACMG

Summary

For recessive disorders, detected in trans with a pathogenic variant

Note: This requires testing of parents (or offspring) to determine phase.

VCEP

Specifications

See **ATM PM3/BP2 table** for approach to assign points per proband, and final PM3 code assignment based on the sum of PM3-related points.

Ataxia Telangiectasia (A-T) is a rare, severe, early-onset disease with some exceptions denoted 'variant' or 'atypical' A-T in which cases phenotypes are more mild with slower progression. Phenotypes associated with A-T are very specific and do not generally require differential diagnosis. Therefore, publications that claim a 'clinical diagnosis of A-T' are taken at face value and granted a 'confident diagnosis. Specific phenotype criteria may qualify for 'confident or 'consistent' diagnosis of A-T based on the below criteria. No additional weight modifications are made for 'atypical' cases if they meet 'confident or 'consistent' criteria as although the disease progression is different, the clinical features are the same.

Variant may not exceed general population frequency $>0.01\%$.

If the variant under assessment has co-occurred with at least 2 different P/LP variants, one co-occurrence must be weighed as phase unknown while the remaining can be assumed in *trans*

Multiple unrelated cases are additive.

- For example, one individual with a 'confident A-T phenotype' is homozygous for a variant scores 2.0 points. Another individual who has a 'consistent A-T phenotype' and has the same variant and another phase-unknown truncating ATM variant scores 1.0 points. The total points towards PM3 are 3.0 points leading to PM3 used as its baseline moderate strength.

CONFIDENT PHENOTYPE (must include Laboratory result)

- Presence of ≥ 2 Laboratory results 1-4 (see notes) -OR-
- Presence of Clinical feature 1a or 1b **AND** presence of Laboratory result 1 or 2 -OR-
- Presence of Clinical feature 2 or 3 **AND** Laboratory result 1 or 2

CONSISTENT PHENOTYPE (does not require laboratory result)

- Presence of two or more Clinical features of ataxia (1a-1e) -OR-
- Presence of one Clinical feature 1a or 1b **AND** either Clinical feature 2 or 3

Clinical features (Neurological and MRI findings):

1. Progressive cerebellar ataxia, manifesting as:
 - a: Progressive truncal/limb ataxia
 - b: Cerebellar degeneration (atrophy of the frontal and posterior vermis and both hemispheres by MRI).
 - c: Oculomotor apraxia (inability to follow an object across visual fields) or abnormal ocular saccades (rapid refixation from one object to another).
 - d: Choreoathetosis or dystonia (involuntary movements; twisting and repetitive movements, abnormal postures).
 - e: Peripheral axonal neuropathy OR Anterior horn cell neuronopathy
2. Oculocutaneous telangiectasia of the conjunctivae, ears, or face.
3. Immunodeficiency (often frequent infections) and/or leukemia/lymphoma.

Laboratory Results:

1. ATM protein levels $\leq 15\%$ of controls in patient fibroblast or lymphoblastoid cell lines. If ATM protein levels are slightly greater than 15%, the ATM kinase activity must be shown to be "negative or low or residual" (see notes).
2. Elevated serum alpha-fetoprotein (AFP) levels $>65\mu\text{g/L}$ in a patient ≥ 2 years old.
3. Increased sensitivity to ionizing radiation in patient fibroblast or lymphoblastoid cell lines.
4. Presence of a 7;14 chromosomal translocation in patient peripheral blood cells ($\geq 5\%$ of cells).

Notes:

1. ATM protein levels $\leq 15\%$ of control levels show $>95\%$ sensitivity and $>98\%$ specificity for diagnosing ataxia-telangiectasia (A-T). Protein levels $>15\%$ may arise due to a missense variant, a leaky splicing variant, a variant resulting in a kinase-dead protein (where protein levels may not be affected), or a diagnosis other than A-T.
2. When assigning case report criteria based solely on laboratory results (i.e., presence of TWO or more of laboratory results 1-4), there is a greater likelihood that the most specific laboratory results #1 and #2 will be available, and that there will be some clinical indication that the individual(s) has A-T.

Very Strong

PM3_VeryStrong ≥ 8 points

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Disease-specific, General recommendation, Gene-specific, Strength
Type:

Strong

PM3_Strong = 4 points

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Disease-specific, General recommendation, Gene-specific, Strength
Type:

Moderate

PM3 = 2 points

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Disease-specific, General recommendation, Gene-specific, Strength
Type:

Supporting

PM3_Supporting = 1 point

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Disease-specific, General recommendation, Gene-specific, Strength
Type:

PM4

Original ACMG Summary

Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-

loss variants.

VCEP Do not use for in-frame insertions or deletions less than a single exon; Use **Specifications** for stop-loss variants, only.

Moderate

Use for stop-loss variants.

Modification General recommendation, Gene-specific
Type:

PM5

Original ACMG Summary

Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.

Example: Arg156His is pathogenic; now you observe Arg156Cys.

Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.

VCEP **Specifications:**

- Based on location of the most C-terminal known pathogenic variant, **p.Arg3047***.
- Use as **PM5_Supporting** (not moderate)
- Do not use for start-loss variants
- Do not use for missense changes: Multiple amino acid substitutions at the same residue can be pathogenic or benign and bioinformatic tools cannot yet confidently distinguish them

Supporting

- Apply to frameshifting or truncating variants with premature termination codons upstream of p.Arg3047.
- Apply to splice variants as with premature termination codons upstream of p.Arg3047 where PVS1_VS(RNA) is applied based on high quality observed splicing impact and must be NMD prone.

Modification Gene-specific, Strength
Type:

PM6

Original ACMG Summary

Assumed de novo, but without confirmation of paternity and maternity.

Not Applicable

Comments: Do not use for AD or AR disease: Informative de novo occurrences have not yet been observed and de novo AR conditions are unlikely to be informed by phase

PP1

Original ACMG

Summary

Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.

Note: May be used as stronger evidence with increasing segregation data.

VCEP

Specifications:

- AR Condition: Affected relatives must have both variants identified in proband.
- AD Condition – Do not use: Co-segregation analysis in lower-penetrance genes can lead to false positive results (PMID 32773770)

Strong

AR Condition: Segregation in ≥ 3 affected relatives

Modification Gene-specific

Type:

Moderate

AR Condition: Segregation in 2 affected relatives

Modification Gene-specific

Type:

Supporting

AR Condition: Segregation in 1 affected relative

Modification Gene-specific

Type:

PP2

Original ACMG

Summary

Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.

Not Applicable

Comments: Do not use: ATM does not have a defined low rate of missense benign variation.

PP3

Original ACMG

Summary

Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).

Caveat: As many in silico algorithms use the same or very similar input for their predictions, each algorithm should not be counted as an independent criterion. PP3 can be used only once in any evaluation of a variant.

VCEP

Specifications:

- NOTE: Splice analysis needs to be considered for all variant types (including missense, frameshift, nonsense, etc. as any variant has the potential to impact splicing which may preclude any expected protein effects)
- NOTE: PP3 for splice predictions may not be applied in addition to PVS1 or PVS1_Variable(RNA) codes.
- Use caution in applying the wrong type of computational evidence (protein vs. RNA) towards the cumulative body of evidence for the opposite mechanism.
- The VCEP uses SpliceAI as a sole predictor due to its ability to accurately predict loss of native splice sites and creation of cryptic sites (Jaganathan et al., 2019). This VCEP recommends SpliceAI thresholds set forth by the SVI in applying PP3 and BP4 to non-canonical splice variants: Apply PP3 for SpliceAI scores ≥ 0.2 and apply BP4 for SpliceAI scores ≤ 0.1 (Walker et al., 2023).
- In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA).

Supporting

- Missense: REVEL $> .7333$
- Splicing: Predicted impact via splicing (SpliceAI ≥ 0.2) for silent, missense/in-frame and for intronic variants outside of donor and acceptor 1,2 sites.

Modification Gene-specific

Type:

PP4

Original ACMG

Summary

Patient's phenotype or family history is highly specific for a disease with a single genetic etiology.

Not Applicable

Comments: Autosomal Dominant: do not use as breast cancer is a disease with multiple genetic etiology (genetic heterogeneity) and there are no features that can readily distinguish hereditary from sporadic causes. Autosomal Recessive: do not use as a separate line of evidence. Such evidence is built into the Ataxia Telangiectasia PM3|BP2 table

PP5**Original ACMG
Summary**

Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.

Not Applicable

This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee. [PubMed : 29543229](#) 

BA1**Original ACMG
Summary**

Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.

VCEP Follow all [SVI general guidance](#) on applying population filters.
Specifications:

Stand Alone

Grpmax Filtering AF **>.5%** in gnomAD v4 dataset

Modification Disease-specific
Type:

BS1**Original ACMG
Summary**

Allele frequency is greater than expected for disorder.

VCEP Follow all [SVI general guidance](#) on applying population filters.
Specifications:

Strong

Grpmax Filtering AF **>.05%** in gnomAD v4 dataset

Modification Disease-specific
Type:

BS2

Original ACMG Summary

Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.

Not Applicable

Comments: Do not use: ATM has incomplete penetrance.

BS3

Original ACMG Summary

Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.

VCEP Specifications: For protein, see detailed notes on ATM-specific assays;
For RNA use code BP7_RNA and modulate strength based on assay quality and quantity (curator discretion).

Moderate

Use when a variant rescues both an ATM specific feature (e.g. phosphorylation of ATM-specific targets) AND radiosensitivity.

Modification Disease-specific, Gene-specific, Strength
Type:

Supporting

Use when a variant rescues EITHER an ATM specific feature OR rescues radiosensitivity.

Modification Disease-specific, Gene-specific, Strength
Type:

BS4

Original ACMG Summary

Lack of segregation in affected members of a family.

Caveat: The presence of phenocopies for common phenotypes (i.e. cancer, epilepsy) can mimic lack of segregation among affected individuals. Also, families may have more than

one pathogenic variant contributing to an autosomal dominant disorder, further confounding an apparent lack of segregation.

Not Applicable

Comments: AD Condition: Co-segregation analysis in low penetrance genes can lead to false positive results (PMID 32773770) AR Condition: Informative instances of lack of co-segregation in A-T families are too rare to be considered for weight at this time and can also be considered for BP2 if biallelic unaffected patients are observed in an A-T family.

BP1

**Original ACMG
Summary**

Missense variant in a gene for which primarily truncating variants are known to cause disease.

Not Applicable

Comments: Do not use: Missense pathogenic variants are known for ATM

BP2

**Original ACMG
Summary**

Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.

VCEP Specifications See **ATM PM3/BP2 table** for approach to assign points per proband, and final BP2 code assignment based on the sum of BP2-related points.

- When assessing homozygous or *in trans* variants (with a likely pathogenic or pathogenic ATM variant) for possible downgrade in an unaffected individual, the individual should be 18 years or older with no evidence of A-T.

Strong

BP2_Strong $\leq$ -4 points

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Type: Disease-specific, General recommendation, Gene-specific, Strength

Moderate

BP2_Moderate = -2 points

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Type: Disease-specific, General recommendation, Gene-specific, Strength

Supporting

BP2 = **-1** point

See ATM PM3/BP2 table for approach to assign points per proband.

Modification Type: Disease-specific, General recommendation, Gene-specific, Strength

BP3

Original ACMG Summary

In frame-deletions/insertions in a repetitive region without a known function.

Not Applicable

Comments: Do not use.

BP4

Original ACMG Summary

Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)

Caveat: As many in silico algorithms use the same or very similar input for their predictions, each algorithm cannot be counted as an independent criterion. BP4 can be used only once in any evaluation of a variant.

VCEP

Specifications:

- NOTE: Splice analysis needs to be considered for all variant types (including missense, frameshift, nonsense, etc. as any variant has the potential to impact splicing which may preclude any expected protein effects)
- NOTE: BP4 for splice predictions may not be applied in conjunction with BP7_Variable(RNA) (a lack of observed RNA defect)
- Use caution in applying the wrong type of computational evidence (protein vs. RNA) towards the cumulative body of evidence for the opposite mechanism.
- The VCEP uses SpliceAI as a sole predictor due to its ability to accurately predict loss of native splice sites and creation of cryptic sites (Jaganathan et al., 2019). This VCEP recommends SpliceAI thresholds set forth by the SVI in applying PP3 and BP4 to non-canonical splice variants: Apply PP3 for SpliceAI scores ≥ 0.2 and apply BP4 for SpliceAI scores ≤ 0.1 (Walker et al., 2023).

- In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA).

Supporting

- Missense: REVEL score $\leq$ **.249**
- Splicing: No predicted impact via splicing (SpliceAI $\leq$ **0.1**).

Modification General recommendation

Type:

BP5

Original ACMG Summary

Variant found in a case with an alternate molecular basis for disease.

Not Applicable

Comments: Do not use: Cases with multiple pathogenic variants have been observed with no noticeable difference in phenotype (e.g. BRCA1 and BRCA2). In addition, ATM has low penetrance and will naturally occur with other pathogenic variants more frequently due to higher tolerance/presence in the general population.

BP6

Original ACMG Summary

Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.

Not Applicable

This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

PubMed : 29543229 [↗](#)

BP7

Original ACMG Summary

A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.

VCEP

- BP7: Synonymous and deep intronic

Specifications:

- Can be used for deep intronic variants beyond (but not including) +7 (donor) and -21 (acceptor)
- May also apply BP4 to achieve Likely Benign
- Is not considered a conflicting piece of evidence against a body of evidence supporting a pathogenic splice defect
- BP7_Variable(RNA): RNA functional studies
 - Lack of aberrant splice defect: Please see PVS1_Variable(RNA) section (above) for guidance on baseline weights and modifications of weight based on quality for RNA assays
 - In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA).

Strong

BP7_Strong(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.

Modification General recommendation

Type:

Moderate

BP7_Moderate(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.

Modification General recommendation

Type:

Supporting

- BP7: Use for synonymous and deep intronic variants defined as further than (but not including) +7 and further than (but not including) -21 at donor and acceptor sites, respectively.
- BP7(RNA): Observed lack of aberrant RNA defect for silent substitutions and intronic variants. Variable weight applied depending on curator discretion of assay quality.

Modification General recommendation

Type:

Rules for Combining Criteria**Pathogenic**

1 Very Strong AND $\geq$ 1 Strong

1 Very Strong AND $\geq$ 2 Moderate

1 Very Strong AND 1 Moderate AND 1 Supporting

1 Very Strong AND ≥ 2 Supporting

≥ 2 Strong

1 Strong AND ≥ 3 Moderate

1 Strong AND 2 Moderate AND ≥ 2 Supporting

1 Strong AND 1 Moderate AND ≥ 4 Supporting

Likely Pathogenic

1 Very Strong AND 1 Moderate

1 Strong AND 1 Moderate

1 Strong AND ≥ 2 Supporting

≥ 3 Moderate

2 Moderate AND ≥ 2 Supporting

1 Moderate AND ≥ 4 Supporting

1 Very Strong (*PVS1, PM3_Very Strong*) **AND 1 Supporting** (*PVS1_Supporting, PS1_Supporting, PS3_Supporting, PM2_Supporting, PM3_Supporting, PM5_Supporting, PP1, PP3*)

Benign

≥ 2 Strong

1 Stand Alone

Likely Benign

1 Strong AND 1 Supporting

≥ 2 Supporting

1 Strong (*BS1, BP2_Strong, BP7_Strong*)

Files & Images

ATM supplementary Tables 1 and 2 : [!\[\]\(dc0c40d45c42e86bc0669168926f812c_img.jpg\)](#)

ClinGen HBOP ACMG Specifications ATM version 1.4: [!\[\]\(b58c23cb5aab1cd63092eda333892cb9_img.jpg\)](#)